Table 1.
Clinical features and survival of patients in the Lena and non-Lena treatment groups.
| Parameter | Patients n/N (%) |
Median (95% CI) | p |
|---|---|---|---|
| Age at diagnosis | ≫ 50 y | 0.868 | |
| Lena | 7/7 | 59.4 (51–68) | |
| Non-Lena | 15/16 | 62.3 (56.2–68.1) | |
| Sex | Male | 0.061 | |
| Lena | 6/7 | ||
| Non-Lena | 12/16 | ||
| Ki67 | ≫ 50% | 0.819 | |
| Lena | 3/7 | 40 (10–70)% | |
| Non-Lena | 6/16 | 30 (15–70)% | |
| MIPI | ≫ 5 | 0.096 | |
| Lena | 5/6 | 6 (5–8) | |
| Non-Lena | 8/17 | 4.5 (3–7) | |
| Treatment response after first relapse | 1 (CR)/2 (PR)/3 (SD)/4 (PD) | 0.083 | |
| Lena | 5/2 | ||
| Non-Lena | 6/5/4/1 | ||
| Auto-HSCT | Yes (0)/No (1) | 0.639 | |
| Lena | 5/2 | ||
| Non-Lena | 10/6 | ||
| Fever, sweating, weight loss | Yes | 0.144 | |
| Lena | 3/7 | ||
| Non-Lena | 4/16 | ||
| CRBN(+) | (+) | 0.350 | |
| Lena | 7/7 | ||
| Non-Lena | 14/16 | ||
| Disease-free survival | Relapse | 0.001 | |
| Lena | 1/7 (14.3%) | 300 (0–1259.7) | |
| Non-Lena | 14/16 (87.5%) | 0 | |
| Overall survival | Death | 0.005 | |
| Lena | 1/7 (14.3%) | 900 (463.6–1336.4) | |
| Non-Lena | 13/16 (81.2%) | 570 (240.4–899.6) |
95% CI, 95% confidence interval; Lena, lenalidomide; MIPI, MCL International Prognostic Index; auto-HSCT, autologous hematopoietic stem cell transplant; CRBN, cereblon.